News|Articles|October 1, 2025

Q4 2025 FDA Preview: 10 Decisions to Watch

Fact checked by: Abigail Brooks, MA, Victoria Johnson

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

The first 3 quarters of 2025 have already been historic for many in medicine, with the US Food and Drug Administration (FDA) clearing the way for new therapies in C3 glomerulopathy, IgG4-related disease, recessive dystrophic epidermolysis bullosa, and even granting the first twice-yearly HIV prevention option.¹

Related to this article

September 20th, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 09/13

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

September 22nd, 2026

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

September 17th, 2026

FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.

September 25th, 2026

FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

Image Credit: US Food and Drug Administration

September 25th, 2026

Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.